Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

This study has been terminated.
(Poor enrollment)
Information provided by (Responsible Party):
Columbia University Identifier:
First received: May 23, 2008
Last updated: November 2, 2012
Last verified: November 2012
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.

Condition Intervention
Growth Hormone Deficiency
Drug: Recombinant Human Growth Hormone
Drug: Recombinant human IGF-1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors in Adult Patients With Growth Hormone Deficiency

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Cardiovascular serum risk markers including lipids, IL-6, CRP and homocysteine [ Time Frame: 2 months ]

Secondary Outcome Measures:
  • Changes in visceral adiposity, intrahepatic and intramyocellular lipids [ Time Frame: 2 months ]
  • Changes in endothelial cell function [ Time Frame: 2 months ]

Enrollment: 5
Study Start Date: January 2008
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Subject taking growth hormone
Drug: Recombinant Human Growth Hormone
300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
Active Comparator: 2
Subject taking recombinant human IGF-1
Drug: Recombinant human IGF-1
30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)

Detailed Description:
Insulin-like growth factor-1 (IGF-1) in some circumstances acts as the mediator of the metabolic effects of growth hormone. However, there is some evidence to suggest that GH and IGF-1 act differently in some metabolic pathways. We will study the differences between GH and IGF-1 when provided as therapy for growth hormone deficiency in adults. Specifically we will be assessing if either medication impacts cardiovascular risk factors and if so do they impact risk factors differently. Ten adult males ages 18-65 who are growth hormone deficient on stable medications and with stable MRI findings (in the event of a known pituitary mass) will be recruited for the study.

Ages Eligible for Study:   25 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male age 25-65 with documented growth hormone deficiency on stable doses x 3 months (at least) of any hormone replacement therapies and with stable MRIs x 2 years in the setting of a known pituitary mass.

Exclusion Criteria:

  • Female gender
  • current GH use or GH use within three months of the study
  • diabetes
  • hypoglycemia
  • liver or kidney disease
  • use of drugs that could increase GH secretion (i.e. L-dopa)
  • alcohol or substance abuse
  • use of investigational drugs within four weeks of our study and use of supraphysiologic doses of steroids within the previous six months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684957

United States, New York
Columbia University, College of Physicians and Surgeons
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Principal Investigator: Pamela U. Freda, M.D. Columbia University
  More Information

Responsible Party: Columbia University Identifier: NCT00684957     History of Changes
Other Study ID Numbers: AAAC2883
Tercica-001 ( Other Identifier: Tercica )
Study First Received: May 23, 2008
Last Updated: November 2, 2012

Additional relevant MeSH terms:
Endocrine System Diseases
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 28, 2017